Maini SR. Infliximab treatment of rheumatoid arthritis. Rheum Dis Clinics N Am. 2004;30:329-347.
Keane J, Geeshon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious disease associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-1265. (Pubitemid 38608568)
Salmon-Ceron D. Recommendations for the prevention and management of in patients taking infliximab. Ann Med Interne (Paris). 2002;153:429-431. (Pubitemid 36033716)
Chapman AL, Munkanta M, Wilkinson KA, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS. 2002;16:2285-2293. (Pubitemid 35449014)
Tam LS, Li EK, Wong SM, et al. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol. 2002;31:296-300. (Pubitemid 35252543)
Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med. 2004;350:2060-2067.
Radhakrishna S, Frieden TR, Subramani R. Association of initial tuberculin sensitivity, age and sex with the incidence of tuberculosis in south India: a 15-year year follow-up. Int J Tuberc Lung Dis. 2003;7:1083-1091.
Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995;2:561-572.
Jacobs M, Samarina A, Grivennikov S, et al. Reactivation of tuberculosis by tumor necrosis factor neutralization. Eur Cytokine Netw. 2007;18:5-13. (Pubitemid 46848053)
